Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419091 | 0.86 | RAB9A (0.74) | SMN1; SMN2MAPTALDH1A1RAB9AALOX5 | |
| SCHEMBL4741823 | 0.86 | RAB9A (0.70) | SMN1; SMN2MAPTALDH1A1RAB9AALOX5 | |
| SCHEMBL10996350 | 0.85 | LMNA (0.58) | SMN1; SMN2MAPTALDH1A1RAB9AALOX5 | |
| SCHEMBL12475206 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2MAPTALDH1A1RAB9AKDM4E | |
| SCHEMBL28795980 | 0.83 | RAB9A (0.57) | SMN1; SMN2MAPTALDH1A1RAB9AKDM4E | |
| SCHEMBL892990 | 0.83 | SMN1; SMN2 (0.76) | SMN1; SMN2MAPTALDH1A1RAB9AKDM4E | |
| SCHEMBL5727163 | 0.81 | ALOX5 (0.52) | SMN1; SMN2MAPTALDH1A1RAB9AALOX5 | |
| SCHEMBL2085303 | 0.81 | CDC7 (0.73) | MAPTALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL3054846 | 0.79 | GAA (0.74) | SMN1; SMN2MAPTALDH1A1RAB9AKDM4E | |
| SCHEMBL28295659 | 0.78 | CDC7 (0.57) | SMN1; SMN2MAPTALDH1A1RAB9AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790723-B2 | Thiazole derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-20050222160-A1 | Thiazole derivatives as phosphodiesterase iv inhibitors | MERCK PATENT GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222160-A1 | Thiazole derivatives as phosphodiesterase iv inhibitors | PDE3B, PDE4B, PDE4A | SMN1; SMN2 3019/4885MAPT 4552/4885ALDH1A1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.